GLYR1 Antibody
Description
GLYR1 Antibody: Structure and Properties
GLYR1 antibodies are designed to target the GLYR1 protein, which contains PWWP, AT-hook, and NAD-binding domains. These antibodies are used for detecting GLYR1 in various experimental settings, including Western blotting (WB), immunohistochemistry (IHC), and immunofluorescence (IF).
Research Findings: GLYR1 Antibody Applications
GLYR1 antibodies have been instrumental in elucidating the protein’s role in cancer, chromatin dynamics, and signaling pathways.
GLYR1 in Cancer
-
Colorectal Cancer: Downregulation of GLYR1 correlates with microsatellite instability (MSI) and poor differentiation. GLYR1 interacts with MLH1, a mismatch repair protein, to regulate its nuclear import. Loss of GLYR1 accelerates G1/S phase transition and reduces sensitivity to 5-fluorouracil (5-FU) via mitochondrial apoptosis inhibition .
-
Breast Cancer: Overexpression of GLYR1 is linked to tumorigenesis, though its exact mechanism remains under investigation .
Chromatin Remodeling and Transcription
GLYR1 binds histone H3K36me3 and facilitates transcriptional activation by destabilizing nucleosomes. It interacts with KDM1B, a histone demethylase, to modify chromatin structure and promote Pol II transcription .
Signaling Pathways
GLYR1 regulates p38 MAPK (MAPK14) signaling under stress conditions, indirectly promoting ATF2 activation via phosphorylation of MAPK14 . Dysregulation of GLYR1 also impacts the PI3K/Akt pathway, affecting p21 expression and cell cycle progression .
GLYR1 Antibody Validation and Specificity
GLYR1 antibodies undergo rigorous validation to ensure specificity. For example:
-
Abcam’s EPR10076B: Demonstrated loss of signal in GLYR1 knockout HEK293T cells, confirming target specificity .
-
Thermo Fisher’s 14833-1-AP: Validated for IHC and WB in human tissues, with no cross-reactivity reported .
Table: Validation Data for Select GLYR1 Antibodies
Tumor Suppression and Drug Resistance
GLYR1 downregulation in microsatellite instability (MSI) colorectal cancer (CRC) is associated with:
-
Accelerated Proliferation: Increased G1/S phase transition via p21 downregulation .
-
Reduced 5-FU Sensitivity: Inhibition of mitochondrial apoptosis pathways .
Epigenetic Regulation
GLYR1’s interaction with EP300 facilitates histone H3K56 acetylation, enhancing transcriptional elongation . This activity is critical for maintaining chromatin accessibility in actively transcribed genes.
Product Specs
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4
Target Background
- Comparative sequence and activity analyses have revealed that AtGLYR1 and AtGLYR2 possess unique structural features absent in Arabidopsis hydroxypyruvate reductases. These features likely contribute to their stronger preference for glyoxylate over hydroxypyruvate. PMID: 24076009
- Research has identified the cytosol as the intracellular location of GLYR1. PMID: 22309191
- Studies have demonstrated that GR1 and GR2 are involved in regulating the detoxification of succinic semialdehyde in plants. [glyoxylate reductase 1] [AtGR1] PMID: 18495640
Q&A
Here’s a structured FAQ collection for GLYR1 antibody research, synthesized from peer-reviewed studies and technical resources:
Advanced Research Questions
How to design experiments investigating GLYR1’s role in microsatellite instability (MSI) CRC?
-
Experimental framework:
How to reconcile contradictory findings about GLYR1’s role in neurological vs. cancer contexts?
-
Analysis strategy:
-
Context-dependent signaling: In neurology, anti-GlyR antibodies target extracellular receptor domains (e.g., PERM/SPS ), while in cancer, nuclear GLYR1 modulates chromatin .
-
Tissue-specific isoforms: Prioritize isoform-specific antibodies (e.g., ab154838 for human studies) .
-
Pathway crosstalk: Map interactions between GlyRα1 (neurological) and GLYR1-MAPK14 (cancer) using dual RNA-seq/proteomics .
-
What advanced techniques complement GLYR1 antibody-based studies?
-
Integrated methods:
Data Interpretation Guidelines
How to analyze GLYR1 IHC results in heterogeneous tumor samples?
-
Scoring protocol:
What controls are essential for GLYR1 Co-IP experiments?
-
Critical controls:
Emerging Research Directions
Can GLYR1 antibodies elucidate epigenetic dysregulation in non-cancer contexts?
-
Case study: In autoimmune encephalitis, anti-GlyR antibodies cause synaptic inhibition defects , while nuclear GLYR1 modulates neuroinflammation via KDM1B . Combine CSF antibody testing (ELISA) and neuronal chromatin profiling .
How to optimize GLYR1 antibody multiplex assays?
-
Multiplex design:
